idecabtagene vicleucel
Sponsors
Celgene Corp., Celgene, Bristol-Myers Squibb, St. Olavs Hospital
Conditions
AL AmyloidosisChronic Lymphocytic LeukaemiaDefined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.Multiple MyelomaMultiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.Myeloma MultipleNewly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell TransplantationNon-Hodgkin Lymphoma
Phase 2
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
RecruitingCTIS2023-504201-36-00
Start: 2018-12-21Target: 214Updated: 2025-10-27
A PHASE 2, MULTI-COHORT, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND IN SUBJECTS WITH CLINICAL HIGH-RISK MULTIPLE MYELOMA
CompletedCTIS2023-505183-10-00
Start: 2019-01-04End: 2025-10-14Target: 20Updated: 2025-09-22
Phase 3
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Active, not recruitingCTIS2022-501346-30-00
Start: 2023-09-25Target: 332Updated: 2025-12-09
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Active, not recruitingNCT06045806
Start: 2023-10-16End: 2029-11-20Updated: 2026-03-05
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma
(RRMM) (KarMMa-3)
Active, not recruitingCTIS2023-509848-10-00
Start: 2019-06-12Target: 138Updated: 2025-11-28
Unknown Phase
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
Active, not recruitingNCT06154902
Start: 2022-07-29End: 2027-12-31Target: 350Updated: 2023-12-04
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
RecruitingNCT06357754
Start: 2023-10-06End: 2038-10-06Target: 50Updated: 2026-01-22
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
RecruitingNCT06698887
Start: 2024-09-11End: 2031-03-27Target: 15Updated: 2024-12-13
The Norwegian Immunotherapy in Multiple Myeloma Study
RecruitingNCT06855121
Start: 2025-01-15End: 2037-12-01Target: 400Updated: 2025-03-03